DOCSLIB.ORG

Vedolizumab Use and the Associations Between Α4β7 Expression and HIV Reservoir in the Gut During Treated Primary HIV Infection --Manuscript Draft

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vedolizumab Use and the Associations Between Α4β7 Expression and HIV Reservoir in the Gut During Treated Primary HIV Infection --Manuscript Draft AIDS Vedolizumab use and the associations between α4β7 expression and HIV reservoir in the gut during treated primary HIV infection --Manuscript Draft-- Manuscript Number: AIDS-D-19-00507 Full Title: Vedolizumab use and the associations between α4β7 expression and HIV reservoir in the gut during treated primary HIV infection Article Type: Correspondence Section/Category: Keywords: HIV; HIV Reservoir; Vedolizumab; α4β7 integrin; GALT Corresponding Author: John Patrick Thornhill, Ph.D., M.B. B.Ch Imperial College London London, UNITED KINGDOM Corresponding Author Secondary Information: Corresponding Author's Institution: Imperial College London Corresponding Author's Secondary Institution: First Author: John Thornhill, PhD MB BCh First Author Secondary Information: Order of Authors: John Thornhill, PhD MB BCh Kate D Lynch, DPhil MBBS Jessica K Skelton, PhD Marcus Dorner, PhD Maryam Khan, BSc Genevieve E E Martin, DPhil MBBS Jonathan Hoare, PhD MBBS Simon Peake, MBBS John Frater, PhD MBBS Sarah Fidler, PhD MBBS Order of Authors Secondary Information: Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation Cover Letter Dr John Thornhill PhD, MB BCh BAO MRC Clinical Research Fellow, St Marys Hospital Campus Imperial College London W2 1NY Tel: +44 (0)1865 271288 Fax: +44 (0)1865 281890 Email: [email protected] 19th June 2019 To the Editor, JA Levy, AIDS Re: Vedolizumab use and the associations between 47 expression and HIV reservoir in the gut during treated primary infection _ A report in Science by Byrareddy, et al. (Sustained virologic control in SIV+ macaques after antiretroviral and 47 antibody therapy. (Science 354, 197-202 (2016)) garnered much interest, suggesting that 47 antibody therapy may be a scalable intervention for use in HIV remission studies. Given the recent interest in this novel intervention, we submit this report characterising 7 expression on CD4 T cells in gut tissue of HIV-infected participants. We observed a correlation between 7 on CD4 T cells and HIV reservoir in both the terminal ileum and rectum. Furthermore, we present the case of an individual treated with 47 antibody therapy during primary HIV infection, showing reduced 7 expression in the gut but no evidence of HIV remission (using a humanised mouse model). Our findings are consistent with an as yet published clinical study (NCT02788175). I confirm that all authors have seen and approved the manuscript, and that all authors have significantly contributed to the work. Also, I can confirm that this work has not been previously published and it is not being considered for publication elsewhere. We believe that our data are of interest to the readership of AIDS. We look forward to hearing from you. With my best wishes Dr John Thornhill, and on behalf of my co-authors Article Vedolizumab use and the associations between 47 expression and HIV reservoir in the gut during treated primary HIV infection John P THORNHILL1,2,3, Kate D LYNCH2, Jessica K SKELTON1, Marcus DORNER1, †, Maryam KHAN1, Genevieve E MARTIN2, Jonathan HOARE1, Simon PEAKE1, John FRATER2,4.5, Sarah FIDLER1,3. 1. Division of Medicine, Wright Fleming Institute, Imperial College, London, UK 2. Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK 3. Imperial College NIHR Biomedical Research Centre 4 National Institute of Health Research Biomedical Research Centre, Oxford, UK 5 Oxford NIHR Biomedical Research Centre † deceased Keywords: HIV; HIV Reservoir; Vedolizumab; α4β7 integrin; GALT Running Head: 47 expression & HIV reservoir in gut Word Count: 743 Corresponding author: John Thornhill, Imperial College London ([email protected]) Funding: This work was supported by an Medical Research Council Fellowship (grant MR/N001265/1 to JT) and a British HIV Association Research Award. 1 Abstract Latent HIV infection in gut CD4+ cells is a barrier to HIV eradication. α4β7 integrin is a gut homing marker expressed on CD4+ cells. Monoclonal antibodies against α4β are being trialled to induce HIV remission. Using gut biopsy samples taken from a cohort of HIV+ individuals treated during primary HIV infection, we characterised β7 expression and HIV DNA in terminal ileum and rectum. We demonstrate an association between HIV DNA and β7 expression in gut, and present the case of a HIV+ individual treated with an α4β7 antibody; finding no evidence of HIV remission by humanized murine viral outgrowth assay. 2 A cure for human immunodeficiency virus (HIV) infection remains elusive with two cases of HIV cure to date[1, 2], both resulting from haematopoietic stem-cell transplantation (HSCT). Whilst interesting as proof of concept, HSCT is associated with high morbidity and mortality and is not scalable; therefore, alternative strategies towards a HIV cure are being explored. Antiretroviral therapy (ART) confers a significant survival benefit but cannot cure HIV infection - a consequence of latently infected CD4+ T-cells, particularly within tissue sites. Gut-associated lymphoid tissue (GALT) serves as one of the main barriers to HIV eradication[3]. α4β7 integrin is a gut homing marker expressed on CD4+ T-cells which allows trafficking of CD4+ T-cells to gut tissue[4]. Furthermore, HIV preferentially infects 47+CD4+ T-cells[5]. Antibodies targeting α4β7 are used to treat inflammatory bowel disease[6]. In SIV-infected primates initial reports suggested treatment with a mononclonal antibody against α4β7 integrin and ART conferred viral control after stopping ART following administration in early infection[7]. We characterized β7 expression and total HIV DNA levels from gut lamina propria mononuclear cells (LPMC) in HEATHER: a UK multicenter prospective cohort of patients with PHI who commenced on ART within three months of PHI diagnosis[8]. In addition, we present the case of an individual from the HEATHER cohort, with ART- treated PHI who also received treatment with a licensed anti-α4β7 integrin monoclonal antibody, vedolizumab, for Crohn’s disease. Matched peripheral blood mononuclear cell (PBMC) and gut LPMC isolated from the terminal ileum and rectum from twenty-four individuals in HEATHER were available. β7 expression - the proportion of memory (CD45RA-CD4+) T cells which were β7 3 positive - was determined by a fluorescence minus one control using flow cytometry. Total HIV DNA was quantified from collagenase digested LPMCs by qPCR. One of the twenty-four individuals was diagnosed with Crohn’s disease five months prior to HIV acquisition (Figure 1a). This 31-year-old MSM tested negative for HIV at his Crohn’s diagnosis and again 2 months later. His Crohn’s disease was initially managed with prednisolone induction and subsequent azathioprine maintenance. Eight months following the diagnosis of Crohn’s disease, he was diagnosed with PHI (with a CD4 T cell count of 475 cells/mm3 and a HIV viral load of 44,038 copies/ml). ART was commenced 28 days after PHI diagnosis with Truvada and raltegravir. Raltegravir was switched to darunavir and ritonavir one month later based on HIV genotype testing. HIV viral load was <20 copies RNA/ml within five months of ART initiation. Twelve months after the diagnosis of Crohn’s disease and three months after PHI, colonoscopy confirmed active ileitis and vedolizumab was commenced. Follow- up biopsy, four months after commencing vedolizumab, showed gross resolution of ileal inflammation with only mild residual chronic active granulomatous colitis on histopathology. Research gut biopsies were taken at this timepoint. β7 expression on memory CD3+CD4+ LPMCs from the overall HEATHER cohort (n=24) correlated with total HIV DNA in the terminal ileum (r=0.67 p=0.0007; Figure 1b) and rectum (r=0.46 p=0.03; Figure 1c). The vedolizumab–treated individual had the lowest β7 expression on CD3+CD4+ LPMCs measured in the terminal ileum (5.2%) and relatively lower expression in the rectum (8.1%) when compared to other HEATHER participants, as well as the highest measured β7 expression on PBMC- derived memory CD4 T cells (24%). Median β7 expression for the HEATHER cohort 4 was 27.1%, 18.3% & 11.0% in the terminal ileum, rectum & PBMC respectively (Figure 1d). Correspondingly, HIV DNA levels in gut LPMCs for the vedolizumab–treated participant were at or just below the median, while his PBMC HIV DNA was the highest measured in the overall cohort (Figure 1e). To confirm the presence of replication competent viral reservoirs in this patient, PBMCs obtained from the vedolizumab- treated participant were subsequently analysed by humanized murine viral outgrowth assay[9]. For this, two timepoints after vedolizumab treatment were evaluated and resulted in detectable serum HIV RNA in mice at days 14 and 28. Together these results suggest that vedolizumab reduced trafficking of β7 expressing CD4 T cells to the gut and support recent work from Uzzan et al. who reported significant attenuation of lymphoid aggregates, most notably in the terminal ileum with anti-α4β7 therapy[10]. These data also demonstrate an association between β7 expression and HIV DNA measured in gut LPMCs. Despite this, and consistent with other work in humanized mice[11] and the first unpublished human study using vedolizumab in HIV+ individuals[12]; our data suggests that while vedoluzimab treatment may confer lower expression of β7 on CD4 T cells in gut LPMCs, vedoluzimab is unlikely to induce sustained viral remission. Authors’ contributions. The study experiments were conceived and designed by JT, KL, GM, JH, SP, JF and SF. Recruitment of the trial samples were performed by, JT, JF, SP, JH & SF. Gut biopsy processing, HIV DNA quantification and flow cytometry experiments were performed by JT, KL and MK. The humanized mouse model experiment was 5 performed by JS and MD. Data was analysed by JT, JS & MD. The paper was written by JT with input from all authors. Acknowledgments: We thank the participants of HEATHER. The HEATHER study is conducted as part of the CHERUB (Collaborative HIV Eradication of Reservoirs: UK BRC) collaboration.
Load more

Recommended publications
  • Pathways to an HIV Cure: Tools for Community and Clinicians AIDS 2020: Virtual Pre-Conference 1 – 3 July
    Pathways to an HIV cure: tools for community and clinicians AIDS 2020: Virtual Pre-Conference 1 – 3 July WEDNESDAY 1 JULY 2020 7am PDT/ 10am EDT/ 4pm CEST & SAST/ 10pm CST/ midnight AEST 45’ Opening Welcome and Introduction Session Semi live Sharon Lewin, The Doherty Institute, The University of Melbourne, Australia Steve Deeks, UCSF, United States Keynote HIV cure strategies relevant to resource-limited settings Thumbi Ndung’u, Africa Health Research Institute, South Africa Community A glass half full: changing attitudes and values to achieve opening an HIV cure Michael Louella, defeatHIV CAB, United States 7.45am PDT/ 10.45am EDT/ 4.45pm CEST & SAST/ 10.45pm CST/ 00.45am AEST (+1d) 45’ Session 1 Advancing the HIV cure field and debunking myths and misconceptions On demand Chair Jessica Salzwedel, AVAC, United States Invited Top 5 myths and misconceptions speakers Advocacy-for-Cure grantees: Philister Adhiambo, Kenya Medical Research Institute, Kenya Owen Mulenga, Treatment Advocacy and Literacy Campaign, Zambia Josephine Nabukenya, MUJHU, Uganda Top 10 advances in laboratory research Lillian Cohn, Chan Zuckerberg Biohub, United States Top 10 advances in clinical research and social sciences Katharine J. Bar, Penn Centre for AIDS Research, United States THURSDAY 2 JULY 2020 6am PDT/ 9am EDT/ 3pm CEST & SAST/ 9pm CST/ 11pm AEST 45’ Session 2 Challenges of clinical trials in cure Semi live Moderator Richard Jefferys, TAG, United States Panelists Analytical Treatment Interruptions in HIV Cure clinical trials - community and clinician perspectives
    [Show full text]
  • Study Protocol
    RIVER Protocol Version 5.0 20-Oct-2016 GENERAL INFORMATION This document was constructed using the MRC CTU Protocol Template Version 3.0. The MRC CTU endorses the Standard Protocol Items: Recommendations For Interventional Trials (SPIRIT) initiative. It describes the RIVER trial, co-ordinated by the Medical Research Council (MRC) Clinical Trials Unit at UCL (herein referred to as MRC CTU), and provides information about procedures for entering participants into it. The protocol should not be used as an aide-memoire or guide for the treatment of other participants. Every care has been taken in drafting this protocol, but corrections or amendments may be necessary. These will be circulated to the registered investigators in the trial, but sites entering participants for the first time are advised to contact RIVER Co-ordinating Centre at, MRC CTU, to confirm they have the most up-to-date version. COMPLIANCE The trial will be conducted in compliance with the approved protocol, the Declaration of Helsinki 1996, the principles of Good Clinical Practice (GCP), Commission Directive 2005/28/EC with the implementation in national legislation in the UK by Statutory Instrument 2004/1031 and subsequent amendments, the UK Data Protection Act (DPA number: Z6364106), and the National Health Service (NHS) Research Governance Framework for Health and Social Care (RGF). SPONSOR Imperial College London is the trial sponsor and has delegated responsibility for the overall management of the RIVER trial to the MRC CTU (RIVER Co-ordinating Centre). Queries relating to Imperial sponsorship of this trial should be addressed to the chief investigator via the Imperial Joint Research Compliance Office.
    [Show full text]
  • Enhanced Normalisation of CD4/CD8 Ratio with Earlier Antiretroviral Therapy at Primary HIV Infection
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Spiral - Imperial College Digital Repository JAIDS Journal of Acquired Immune Deficiency Syndromes Publish Ahead of Print DOI: 10.1097/QAI.0000000000001013 Enhanced normalisation of CD4/CD8 ratio with earlier antiretroviral therapy at Primary HIV Infection John Thornhill 1, Jamie Inshaw 2, Pontiano Kaleebu 3, David Cooper 4, Gita Ramjee 5, Mauro Schechter 6, Giuseppe Tambussi 7, Julie Fox 8, Miriam Samuel 8, Jose Maria Miro 9, Jonathan Weber 1, Kholoud Porter 2, Sarah Fidler 1 on behalf of UK Register of HIV Seroconverters and SPARTAC Trial Investigators 1. Imperial College, Department of Medicine, London, United Kingdom; 2. MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, United Kingdom; 3. Medical Research Council, Uganda Virus Research Institute, Entebbe, Uganda; 4. University of New South Wales, Kirby Institute, Sydney, Australia; 5. Medical Research Council, HIV Prevention Unit, Durban, South Africa; 6. Projeto Praça Onze, Hospital Escola Sao Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 7. Ospedale San Raffaele, Division of Infectious Diseases, Milan, Italy; 8. Kings College London, Guys and St Thomas' NHS Trust, London, United Kingdom; 9. University of Barcelona, Hospital Clinic, Barcelona, Spain †Correspondence should be addressed to: John Thornhill, Winston Churchill Wing, St Mary’s Hospital, Praed St. London W2 1NY Email: [email protected] Keywords: Primary HIV Infection, Seroconversion, Acute HIV infection, CD4/CD8 ratio, CD4:CD8, Early Antiretroviral therapy Conflicts of Interest & Source of Funding: The SPARTAC Trial was funded by the Wellcome Trust (Grant Reference Number: 069598).
    [Show full text]
  • CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA
    ORIGINAL RESEARCH published: 04 May 2018 doi: 10.3389/fimmu.2018.00928 CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA Genevieve E. Martin 1†, Matthew Pace 1†, John P. Thornhill 1,2†, Chansavath Phetsouphanh 1, Jodi Meyerowitz 1, Morgane Gossez 1, Helen Brown 1, Natalia Olejniczak 1, Julianne Lwanga 3, Gita Ramjee 4, Pontiano Kaleebu 5, Kholoud Porter 6, Christian B. Willberg 1,7, Paul Klenerman1,7, Nneka Nwokolo 8‡, Julie Fox 3‡, Sarah Fidler2‡ and John Frater 1,7*‡ On Behalf of the CHERUB Investigators 1 Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, 2 Division of Medicine, Wright Fleming Institute, Imperial College, London, United Kingdom, 3 Department of Genitourinary Medicine and Infectious Disease, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, 4 HIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa, 5 Uganda Virus Research Institute (MRC), Entebbe, Uganda, 6 Research Department of Infection and Population Health, University College London, Edited by: London, United Kingdom, 7 NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom, 8 Chelsea and Guido Poli, Westminster Hospital, London, United Kingdom Vita-Salute San Raffaele University, Italy Reviewed by: Efforts to both characterize and eradicate the HIV reservoir have been limited by the Mirko Paiardini, rarity of latently infected cells and the absence of a specific denoting biomarker. CD32a Emory University School of Medicine, United States (FcγRIIa) has been proposed to be a marker for an enriched CD4 T cell HIV reservoir, Paul Urquhart Cameron, but this finding remains controversial.
    [Show full text]
  • Investigating Neuronal Injury in a HIV Cure Strategy
    12th International Symposium on Neuropsychiatry and HIV 14th June 2019 Investigating neuronal injury in a HIV cure strategy Jasmini Alagaratnam Clinical Research Fellow Imperial College London Why can’t ART cure HIV? The viral reservoir HIV reservoir sites Major reservoirs HIV infects CD4+ cells Dormant memory T cells in lymph nodes and blood2 Some become Macrophages and resting memory cells; dendritic cells in various tissues (especially in ‘reservoir’ lymph nodes, gut and central nervous system)2 Research into HIV cure has intensified Data on the safety aspects of HIV cure strategies are limited1 1. Dubé K. Trends Microbiol. 2014 Oct;22(10):547-9 Kick and kill Potential CNS risks of ‘kick and kill’ 1. Direct neuronal injury: • Viral rebound releasing viral proteins which are neurotoxic • LRA toxicities 2. Indirect neuronal injury: • CNS IRIS, CD8+ mediated encephalitis • Following HIV vaccines which may modify immune responses • Inflammation & immune activation • Following viral rebound or HIV vaccines 3. Removal of cells with crucial function 4. Reversal of other integrated viruses in a resting phase CSF Neurofilament Light Chain protein (NFL) • NFL maintains structure of axons • Sensitive and dynamic biomarker of active neuroaxonal damage in the CNS • Elevated concentrations are reported in a variety of neurodegenerative conditions including HIV Plasma neurofilament light chain (NFL) • Highly sensitive assay measuring plasma NFL has recently been developed • Strongly correlates with CSF NFL • Removes the barriers of repeated CSF sampling
    [Show full text]
  • Sarah J. Fidler, MBBS
    A summary of the evidence, questions and the trials addressing TasP? Sarah Fidler Imperial College London Overview • What is the evidence • Is a trial needed • What are the current trials • PopART HPTN071 ART for prevention: background • HIV incidence continues to be unacceptably high especially in many countries in Africa • Unless incidence can be reduced dramatically it will become increasingly difficult over time to sustain effective ART services • Lack of proven effective HIV prevention strategies • Risk of HIV transmission closely correlated with HIV viral load and ART can be used to reduce HIV viral load and hence infectivity • Current guidelines limit ART to those with late-stage HIV infection (CD4<350) but most transmissions occur before ART initiation Goals of ART as prevention To significantly reduce/eliminate onward HIV transmission at a population level- whilst ensuring universal access to lifelong treatment for all living with HIV Additional individual benefits of TasP • Reduction of morbidity and mortality in those receiving ART by earlier onset of treatment • Reduction of TB and other HIV-related illnesses • (Potential) elimination of mother to child HIV transmission • (Eventual) cost savings • Normalisation of HIV and reduction in HIV-related stigma Rakai Study of viral load and HIV transmission Quinn et al, NEJM 2000 HPTN 052 • 1763 HIV-discordant couples in 9 countries, CD4=250-550 • Stopped for efficacy • 39 HIV-ve partners were infected of which 29 were linked virologically to the HIV+ study partner • Of these 29 only
    [Show full text]
  • Full Recommendations: Towards an Hiv Cure 2016 Contents
    FULL RECOMMENDATIONS: TOWARDS AN HIV CURE 2016 CONTENTS INTRODUCTION ............................................................................................................................................................................... 4 1. MOLECULAR BIOLOGY OF HIV LATENCY AND REVERSAL STRATEGIES .............................................................7 2. VIRAL RESERVOIRS, IMMUNOLOGY OF HIV PERSISTENCE AND “KILL” STRATEGIES ..................................13 3. MODELS FOR HIV CURE OR SUSTAINABLE REMISSION AND PAEDIATRIC HIV CURE ...............................21 4. GENE AND CELL THERAPY ................................................................................................................................................... 27 5. NOVEL BIOMARKERS AND TECHNOLOGIES TO ANALYSE AND QUANTIFY HIV RESERVOIRS .............33 6. SOCIAL SCIENCES AND HEALTH SYSTEMS RESEARCH ...........................................................................................39 7. METHODOLOGY ........................................................................................................................................................................46 8. ACKNOWLEDGEMENTS ..........................................................................................................................................................46 9. BIBLIOGAPHY .............................................................................................................................................................................. 47 FULL RECOMMENDATIONS
    [Show full text]
  • A Systematic Review of Definitions of Extreme Phenotypes of HIV Control
    EDITORIAL REVIEW A systematic review of definitions of extreme phenotypes of HIV control and progression Deepti Gurdasania,b, Louise Ilesa,b, David G. Dillona,b, Elizabeth H. Younga,b, Ashley D. Olsonc, Vivek Naranbhaid,e, Sarah Fidlerf, Effrossyni Gkrania-Klotsasg, Frank A. Posth, Paul Kellama,i, Kholoud Porterc, Manjinder S. Sandhua,b, on behalf of the UK HIV Genomics Consortium The study of individuals at opposite ends of the HIV clinical spectrum can provide invaluable insights into HIV biology. Heterogeneity in criteria used to define these individuals can introduce inconsistencies in results from research and make it difficult to identify biological mechanisms underlying these phenotypes. In this systematic review, we formally quantified the heterogeneity in definitions used for terms referring to extreme phenotypes in the literature, and identified common definitions and components used to describe these phenotypes. We assessed 714 definitions of HIV extreme phenotypes in 501 eligible studies published between 1 January 2000 and 15 March 2012, and identified substantial variation among these. This heterogeneity in definitions may represent important differences in biological endophenotypes and clinical progression profiles of individuals selected by these, suggesting the need for harmonized definitions. In this context, we were able to identify common components in existing definitions that may provide a framework for developing consensus definitions for these phenotypes in HIV infection. ß 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins AIDS 2014, 28:149–162 Keywords: definitions, elite controllers, extreme-trait designs, HIV, HIV controllers, long-term nonprogressors, phenotypes, slow progressors, systematic review, viremic controllers Introduction remain asymptomatic for several years, others show rapid immunological and clinical progression.
    [Show full text]
  • IAS Towards an HIV Cure Symposium
    Journal of Virus Eradication 2015; 1: e1–e6 CONFERENCE REPORT IAS Towards an HIV Cure Symposium: people focused, science driven 18–19 July 2015, Vancouver, Canada Sarah Fidler1, John Thornhill1, Eva Malatinkova2, Robert Reinhard3, Rosanne Lamplough4, Jintanat Ananworanich5, Ann Chahroudi6 1 Department of Medicine, Imperial College London, UK 2 HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University and Ghent University Hospital, Ghent, Belgium 3 University of Toronto, Toronto, Canada; and Institut de Recherches Cliniques de Montréal, Montréal, Canada 4 International AIDS Society, Geneva, Switzerland 5 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA; United States Military HIV Research Program, Bethesda, MD, USA 6 Department of Pediatrics, Emory University School of Medicine Atlanta, Georgia, USA Abstract The International AIDS Society (IAS) convened the Towards an HIV Cure Symposium on 18–19 July 2015 in Vancouver, Canada, bringing together researchers and community to discuss the most recent advances in our understanding of HIV latency, reservoirs and a summary of the current clinical approaches towards an HIV cure. The symposium objectives were to: (1) gather researchers and stakeholders to present, review, and discuss the latest research towards an HIV cure; (2) promote cross-disciplinary global interactions between basic, clinical and social scientists; and (3) provide a platform for sharing information among scientists, clinicians, funders, media and civil society. The symposium examined basic molecular science and animal model data, and emerging and ongoing clinical trial results to prioritise strategies and determine the viral and immune responses that could lead to HIV remission without antiretroviral therapy.
    [Show full text]
  • Novel Therapies / Hopes for HIV Cure in Perinatally Acquired HIV Positive Adolescents
    Novel therapies / hopes for HIV cure in perinatally acquired HIV positive adolescents 1st author: Thomas Joshua Pasvol (corresponding author) – Imperial College London 16 The Crescent London E17 8AB [email protected] 2nd author: Caroline Foster – Imperial College Healthcare NHS Trust 3rd author: Sarah Fidler – Imperial College London Abstract: Successful roll-out of paediatric antiretroviral therapy (ART) has led to a significant increase in survival of adolescents and young people growing up with HIV. Those on suppressive ART since childhood represent a unique group particularly well-positioned to interrupt ART and achieve post-treatment control (PTC), or HIV remission. This maybe a consequence of early and sustained treatment since infancy, the small size of the HIV reservoir, the presence of a functioning thymus and a more “flexible” immune system better able to respond to novel immune therapeutic interventions when compared to adults who acquired HIV at a time of immunological maturity and thymic involution. Recent findings: In the past year there have been additional case reports of post-treatment viral control amongst perinatally acquired HIV adolescents and young adults (PaHIV-AYA). In this article we review and compare the characteristics of post-treatment control in PaHIV- AYA and discuss the potential implications of these observations for the growing population of adolescents living with HIV. The correlation between low levels of HIV DNA and seroreversion may provide a feasible screening tool to select candidates most suitable for future intervention studies and viral remission. Conclusion: Whilst is is premature to anticipate an HIV cure, there is much anticipation that with early ART and additional interventions to perturb the residual viral reservoir, future viral remission off ART might be feasible for PaHIV-AYA.
    [Show full text]
  • Towards a Cure: Will It Ever Be Truly Achievable?
    TOWARDS A CURE: WILL IT EVER BE TRULY ACHIEVABLE? Scott Mullaney, RN BSN MSc Senior Research Charge Nurse HIV Clinical Trials Centre Imperial College London St. Mary’s Hospital IS PHI the best time to move towards an HIV cure? HIV if untreated can lead to AIDS ART works by blocking new virus production Evolution of HIV Treatment HOW DID WE STOP AIDS? ANTIRETROVIRAL THERAPY IT WORKS!! ART has had the most dramatic change to survival for people living with HIV Strategic Timing of Anti Retroviral Treatment: START study Why can’t ART cure HIV? How could we consider a “Cure” for HIV? Functional cure or remission Sterilising Cure • No viral replication off • No latently infected cells antiretroviral therapy and so no detectable virus • There may be the DNA AND RNA occasional latently infected cells, (Detectable viral DNA) • No detectable viral but no/little evidence of viral reservoir transcription or replication • No detectable viral • No risk of onward transcription transmission • No ongoing immunological • Timothy Brown damage The HIV reservoir What is it? Where is it? Why is it a problem? The HIV reservoir is like a needle in a haystack, if we can’t find - is it not there? What assays should be used to measure the reservoir/determine “cure”? • Viral outgrowth assays? • T-cell activation assays? • q-PCR-based assays? Anatomical reservoirs Bridging the gap from current cART to cure CURE! Current CURE? cART cART, combination antiretroviral therapy What if we give ART VERY early? HIV 3 DAYS The “Mississippi baby – Cured? Has one Baby been “cured”
    [Show full text]
  • Docteur De L'université De Bordeaux
    T ¡¢ £ ¤ ¥ ¦¢ £§T¦£ POUR OBTENIR LE GRADE DE DOCTEUR DE L’UNIVERSITÉ DE BORDEAUX ÉCOLE DOCTORALE : Sociétés, Politique et Santé publique SPÉCIALITÉ : Santé Publique OPTION: Epidémiologie Par Delphine PERRIAT Intégration et généralisation des stratégies du type “Dépistage et traitement universels du VIH” en Afrique sub-saharienne Exemple de l’essai ANRS 12249 TasP Integration and generalization of “Universal Test and Treat” strategies for HIV in sub-Saharan Africa The ANRS 12249 TasP Trial and beyond Sous la direction de : Joanna ORNE-GLIEMANN et François DABIS Soutenue le 12 décembre 2017 Membres du jury : M. ANGLARET, Xavier, DR, Inserm U1219, Université de Bordeaux, France Président Mme DESGRÉES DU LOÛ, Annabel, DR, Institut de Recherche pour le Développement, Paris, France Rapporteur Mme FIDLER, Sarah, Professeur, Imperial College, London, United Kingdom Rapporteur M. BÄRNIGHAUSEN, Till, Professeur, Heidelberg Institute of Public Health, Heidelberg, Allemagne Examinateur M. FONTANET, Arnaud, Professeur, Institut Pasteur, Paris, France Examinateur ADMINISTRATIVE INFORMATION The present PhD was realized within the “Infectious diseases in lower-income countries” (IDLIC) research team, in the Bordeaux Population Health research centre INSERM U1219, University of Bordeaux, located 146 rue Léo Saignat, 33076 BORDEAUX 2 FINANCING This PhD thesis was realized thanks to a PhD grant of the French Ministry of Higher Education and Research, via the EHESP School of Public Health (Ecole des Hautes Etudes en Santé Publique). 3 EPIGRAPH “Toutes les généralisations sont fausses, y compris celle-ci” “All generalizations are dangerous, even this one.” - Alexandre Dumas 4 ACKNOWLEDGEMENTS This PhD thesis is the result of three years of work during which I was lucky to benefit from the support of many people that I would like to sincerely thank.
    [Show full text]